Kyowa Kirin

4151 · TSE · Japan

Public Market Listing

4151TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Kyowa Kirin are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(9 total)
9Total Assets
6Approved
0Phase 3 / Filed
3Phase 1–2 / Early
10Diseases
Quick filter:
Showing 9 of 9 assets
Target & Modality
Benralizumab(Fasenra)
Approved
IL-5 receptor alpha · IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC) · IL-5 receptor alpha (IL5RA) on eosinophils/basophilsMonoclonal antibody
Asthma
brodalumab(Siliq)
Approved
IL-17 receptor AMonoclonal antibody
Psoriasis
istradefylline(Nourianz)
Approved
adenosine A2ASmall molecule
Parkinson's Disease
Saxagliptin(Onglyza)
Approved
DPP-4Small molecule
Type 2 Diabetes
Approved
NHE3 (sodium/hydrogen exchanger isoform 3)Small molecule
Chronic Kidney DiseaseHyperphosphatemia
Approved
MeninSmall molecule
Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
Phase 1
EpCAM (CD326) / CD40Multispecific antibody
Non-Small Cell Lung Cancer
Phase 1
TIM-3
Acute Myeloid Leukemia
Phase 1
Undisclosed / early pipelineBiologic (subtype unspecified)
Hypertension

Discontinued programmes (2)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Est. primary completion 2026-12-23 · NCT05692180 · CT.gov ↗
What to watch
2027 (1)
March 2027 (1)
ZiftomenibPhase 2Acute Myeloid Leukemia (AML)
Est. primary completion 2027-03 · NCT07623616 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Benralizumab · FasenraPhase 3Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
Est. primary completion 2028-02-20 · NCT06512883 · CT.gov ↗
What to watch
October 2028 (1)
ZiftomenibPhase 1/2Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia …
Est. primary completion 2028-10-16 · NCT04067336 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Benralizumab · FasenraPhase 3Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
Est. primary completion 2029-12-27 · NCT07444567 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
ZiftomenibPhase 3Acute Myeloid Leukemia (AML)
Est. primary completion 2031-11 · NCT07007312 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 November 2025ApprovalZiftomenibFDA Boxed Warning on Ziftomenib (NDA220305)
US, FDA · FDA · Source ↗
17 September 2025Topline resultBenralizumabRESOLUTE (NCT04053634) Phase 3 missed its primary endpoint
AstraZeneca PLC · Source ↗
9 September 2025Topline resultrocatinlimabRocatinlimab ASCEND long-term extension top-line results
8 March 2025Topline resultrocatinlimabIGNITE Phase 3 top-line results
19 December 2024WithdrawalDaprodustatFDA withdraws approval of NDA 216951 (Federal Register 2024-26913)
US, FDA · Source ↗

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.3B$676M$1.4B—report ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$3.3B$685M$1.6B—report ↗
2023-FY$3.2B$514M$2.9B—report ↗
2022-FY$3.0B$482M$2.6B—report ↗